Immune cells as targets for cardioprotection: new players and novel therapeutic opportunities

I Andreadou, HA Cabrera-Fuentes… - Cardiovascular …, 2019 - academic.oup.com
New therapies are required to reduce myocardial infarct (MI) size and prevent the onset of
heart failure in patients presenting with acute myocardial infarction (AMI), one of the leading …

Innate immunity as a target for acute cardioprotection

CJ Zuurbier, A Abbate… - Cardiovascular …, 2019 - academic.oup.com
Acute obstruction of a coronary artery causes myocardial ischaemia and if prolonged, may
result in an ST-segment elevation myocardial infarction (STEMI). First-line treatment involves …

Serum metal ion-induced cross-linking of photoelectrochemical peptides and circulating proteins for evaluating cardiac ischemia/reperfusion

P Hao, H Li, L Zhou, H Sun, J Han, Z Zhang - ACS sensors, 2022 - ACS Publications
Patients having experienced the ischemia-reperfusion process are particularly vulnerable to
subsequent heart attacks because this process can induce myocardial fibrosis, hallmarked …

Multifunctional role of chymase in acute and chronic tissue injury and remodeling

LJ Dell'Italia, JF Collawn, CM Ferrario - Circulation research, 2018 - Am Heart Assoc
Chymase is the most efficient Ang II (angiotensin II)–forming enzyme in the human body and
has been implicated in a wide variety of human diseases that also implicate its many other …

Post-ischemic myocardial inflammatory response: a complex and dynamic process susceptible to immunomodulatory therapies

NJ Pluijmert, DE Atsma, PHA Quax - Frontiers in Cardiovascular …, 2021 - frontiersin.org
Following acute occlusion of a coronary artery causing myocardial ischemia and
implementing first-line treatment involving rapid reperfusion, a dynamic and balanced …

The roles of intracellular proteolysis in cardiac ischemia–reperfusion injury

B Hartley, W Bassiouni, R Schulz, O Julien - Basic Research in Cardiology, 2023 - Springer
Ischemic heart disease remains a leading cause of human mortality worldwide. One form of
ischemic heart disease is ischemia–reperfusion injury caused by the reintroduction of blood …

[HTML][HTML] Novel insight into the in vivo function of mast cell chymase: lessons from knockouts and inhibitors

G Pejler - Journal of Innate Immunity, 2020 - karger.com
Mast cells are now recognized as key players in diverse pathologies, but the mechanisms by
which they contribute in such settings are only partially understood. Mast cells are packed …

[HTML][HTML] Extracellular vesicles derived from microRNA-150-5p-overexpressing mesenchymal stem cells protect rat hearts against ischemia/reperfusion

H Ou, H Teng, Y Qin, X Luo, P Yang, W Zhang… - Aging (Albany …, 2020 - ncbi.nlm.nih.gov
An intriguing area of research has demonstrated the ability of extracellular vesicles (EVs) as
biological vehicles for microRNAs (miRNAs) transfer. Mesenchymal stem cells (MSCs) …

Inhibitors of NLRP3 inflammasome in ischemic heart disease: focus on functional and redox aspects

P Pagliaro, C Penna - Antioxidants, 2023 - mdpi.com
Myocardial ischemia-reperfusion injury (MIRI) is caused by several mechanisms, including
the production of reactive oxygen species (ROS), altered cellular osmolarity, and …

The impact of the renin-angiotensin-aldosterone system on inflammation, coagulation, and atherothrombotic complications, and to aggravated COVID-19

M Ekholm, T Kahan - Frontiers in Pharmacology, 2021 - frontiersin.org
Atherosclerosis is considered a disease caused by a chronic inflammation, associated with
endothelial dysfunction, and several mediators of inflammation are up-regulated in subjects …